Viridian Therapeutics Net Loss History

VRDN Stock  USD 26.98  -0.86  -3.09%   
Viridian Therapeutics' Net Loss is heading growing. The latest Net Loss for Viridian Therapeutics is -4.24. That compares to -4.0399 the year before, a 4.72% move lower. Complete Financial Overview
 
Net Loss  
 First Reported
2010-12-31
 Previous Quarter
-4.04
 Current Value
-4.24
 Quarterly Volatility
15.27037487
Macro event markers
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Viridian Therapeutics's Net Loss is influenced by both company-specific factors and broader sector dynamics.

Latest Viridian Therapeutics' Net Loss Growth Pattern

Viridian Therapeutics's Net Loss trajectory spans 14 fiscal years in the chart below. The latest annual change of 4.72% continues a growing multi-year pattern. Flat stretches in Viridian Therapeutics' Net Loss may reflect operational stability or a pause between growth phases.
Net Loss10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Net Loss Trend Statistics

Arithmetic Mean-19.73
Coefficient Of Variation-77.39
Mean Deviation 12.20
Median-17.57
Standard Deviation 15.27
Sample Variance 233.18
Range48.4871
R-Value 0.79
Mean Square Error 95.38
R-Squared 0.62
Significance 0.0002
Slope 2.37
Total Sum of Squares 3,731

Viridian Therapeutics Net Loss History

2026 -4.24
2025 -4.04
2024 -3.98
2023 -5.31
2022 -4.05
2021 -6.66
2020 -31.13
2019 -20.04
2018 -16.57
2017 -20.66
2016 -17.57
2015 -21.0
2014 -52.46
2013 -11.48

Methodology, Assumptions & Data Sources

This chart follows Viridian Therapeutics's Net Loss across recent years. Year-over-year changes are the easiest way to spot turning points.

For Viridian Therapeutics, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Sell-side coverage, where present, supplements the data shown. Intraday timing differences may exist. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Last reviewed on February 25th, 2026